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BACKGROUND: As most children with acute lymphoblastic leukaemia (ALL) achieve long-term survival, minimising late effects of
treatment is a priority. Acute lymphoblastic leukaemia survivors treated historically with protocols including cranial irradiation
demonstrate increased weight gain.
METHODS: We retrospectively studied all 134 patients treated on the MRC/UKALL97 protocol (without cranial irradiation as standard
therapy) at a single centre, with 77 inclusions. Height-, weight- and body mass index (BMI) standard-deviation scores (SDS) were
recorded at diagnosis and annually until 3 years out (YO) from end of treatment (EoT); changes across time were explored using a
univariate model (significance Pp0.001 to account for multiple comparisons).
RESULTS: Whole-group height SDS was lower from 1 year into treatment until 2YO, whereas weight- and BMI-SDS remained higher
until 3YO. In females, height-SDS was lower until EoT, but higher weight- and BMI-SDS persisted until 3YO. In males, height-SDS
was lower at EoT and at 2YO; differences in BMI-SDS had resolved by 2YO. By WHO criteria, more patients were overweight or
obese at 3YO than at diagnosis (P¼0.01).
CONCLUSION: Survivors of childhood ALL, particularly females, exhibit adverse changes in height-, weight- and BMI-SDS, which arise
during treatment and persist into follow-up. Patients should be supported with appropriate dietary and lifestyle advice during ALL
treatment and follow-up, which may minimise these changes and reduce associated long-term morbidity.
British Journal of Cancer (2011) 104, 746–749. doi:10.1038/bjc.2011.16 www.bjcancer.com
Published online 15 February 2011
& 2011 Cancer Research UK
Keywords: acute lymphoblastic leukaemia; auxological; body mass index; childhood; late effects; weight
                                                   
Acute lymphoblastic leukaemia (ALL) is the most common
childhood cancer. As over 80% of patients now achieve 10-year
overall survival (Mitchell et al, 2010), attention now focuses on
minimising sequelae of the condition and its treatment. Increased
obesity has been reported amongst survivors of childhood ALL,
with cranial irradiation as a major risk factor (Odame et al, 1994),
with one study demonstrating obesity in 50% of ALL survivors at
final height (Didi et al, 1995). The most recent UK report, which
included a cohort of unirradiated patients treated on the MRC/
UKALL XI protocol, demonstrated raised body mass index
standard deviation scores (BMI-SDS) in both males and females,
from diagnosis to the end of treatment (EoT), but this increase did
not persist to last follow-up (Craig et al, 1999).
More recent treatment protocols have replaced cranial irradia-
tion with intrathecal chemotherapy as standard central nervous
system disease prophylaxis and treatment. Published reports on
the auxological effects of these changes are conflicting. An
increased incidence of overweight and obesity is reported amongst
some US cohorts (Baillargeon et al, 2007; Chow et al, 2007).
However, a retrospective report from the US Childhood Cancer
Survivor Study did not identify any BMI increase in ALL survivors
treated with chemotherapy alone, although self-reported heights
and weights were used and adult thresholds of overweight and
obese used (Garmey et al, 2008).
There have been no reports on auxological parameters in a UK
cohort treated on a contemporary treatment protocol without
cranial irradiation as standard therapy. We therefore performed a
retrospective longitudinal single-centre study to evaluate the
relative contributions of height and weight to BMI at different
time points during treatment and follow-up in patients treated on
the MRC/UKALL97 protocol.
PATIENTS AND METHODS
Retrospective case-note analysis was performed on all children
with ALL enrolled on the MRC/UKALL97 protocol at Adden-
brooke’s Hospital, Cambridge, UK between 1997 and 2003 and
aged 1–16 years at diagnosis. Anonymised demographic and
treatment data was recorded between January and April 2008.
Height and weight measurements at ALL diagnosis and annual
time points until 3 years out (YO) from EoT were collected. Body
mass index was calculated at each time point using the standard
formula: weight (kg)/height (m)
2. Height-, weight- and BMI-SDS
were calculated relative to British age- and population-referenced
normative data (Cole, 1990). Exclusion criteria were relapse, death,
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sirradiation (cranial or testicular), bone marrow transplant or other
co-existing condition affecting long-term growth (namely chronic
liver disease, which was presumed to occur as a result of use of
6-thioguanine during ALL treatment).
Analyses were performed using SPSS version 10 (SPSS (UK)
Limited, IBM, Woking, UK). Changes in height-, weight- and BMI-
SDS across time from diagnosis were explored using a univariate
model including each of these as the dependent variable,
incorporating both the time from diagnosis and subject identifica-
tion. Post-hoc analysis for time was performed using Dunnett’s
two-sided test. To account for multiple comparisons, a P-value
p0.001 (two-tailed) was considered significant. Between-group
differences in height-, weight- and BMI-SDS changes between
diagnosis and 3YO by gender, diagnostic white cell count (WCC;
o or X50 10
9l
 1), MRC/UKALL97 treatment regimen (A/B/high
risk) and steroid randomisation (prednisolone/dexamethasone)
were performed using one-way analysis of variance for patients
with complete data sets to 3YO. Overall frequency of overweight
(BMI-SDS 1.3–2.3) and obesity (BMI-SDS 42.3) in patients at
diagnosis and 3YO were determined according to standard WHO
criteria (Cole et al, 2000) and between-group differences examined
using w
2-test (Po0.05 significant).
RESULTS
Study patients/demographics
From a total of 134 patients enrolled, 57 (42%) were excluded:
28 died, 9 relapsed, 7 received irradiation (6 cranial, 1 testicular),
1 patient underwent bone marrow transplant, 9 developed chronic
liver disease, 2 had insufficient auxological data at diagnosis and
1 patient transferred to adult care. Of the 77 patients included,
37 (48%) were male and 40 (52%) were female. Median (range) age
(year) at diagnosis was 4.6 (1.1–15.9), with no gender difference
(females 4.3 (1.1–13.1), males 5.6 (1.5–15.9)). Median age at 3YO
was 9.8 years in females and 11.8 years in males, giving an overall
median of 10.1 (6.5–20.1). At the time of data capture, 13 of the 77
patients had not reached 3YO and a further 11 either did not have
measurements recorded or were lost to follow-up. Distribution of
ethnic groups reflected that of the local population (87% White
British).
Disease/treatment characteristics
Of the 77 patients included, 67 patients (87%) had low WCC at
diagnosis (o50 10
9l
 1) and 10 (13%) were high count
(X50 10
9l
 1). In total, 52 patients (67.5%) were treated on
MRC/UKALL97 protocol Regimen-A, 19 patients (24.7%) on
Regimen-B and 6 patients (7.8%) on the high-risk protocol,
consistent with overall UK figures. A total of 30 patients (39%)
received prednisolone and 47 received (61%) dexamethasone – the
unequal distribution attributable to dexamethasone becoming
standard therapy during the MRC/UKALL97 study because of its
superior event-free survival (Mitchell et al, 2005). Most male
patients received 2 years of maintenance ALL therapy (i.e.,
approximately 3 years treatment in total), and therefore received
a greater cumulative dose of steroid treatment than females, who
only received 1 year of maintenance.
Whole group and gender subgroup comparisons
Adjusted mean height-, weight- and BMI-SDS for whole group and
gender subgroups at diagnosis, 1 year into treatment, EoT and
yearly intervals to 3YO are shown in Table 1. Height: whole-group
mean height-SDS was reduced from 1 year into treatment to 2YO.
For the male subgroup, mean height-SDS was reduced at EoT and
2YO, whereas for females the scores were reduced at 1 year into
treatment and EoT (Figure 1A). Weight: whole-group mean
weight-SDS was higher from EoT to 3YO. When analysed by
gender, mean weight-SDS for males was unchanged. Females
showed raised mean weight-SDS at all time points from 1YO until
3YO (Figure 1B). Body mass index: whole-group mean BMI-SDS
was higher from 1 year into treatment and still raised at 3YO. In
males, the mean BMI-SDS was elevated from 1 year into treatment
until 1YO. In the female subgroup, mean BMI-SDS was elevated
from EoT and at all time points to 3YO (Figure 1C).
Table 1 Height-, weight- and BMI-SDS in whole group and male and female subgroups from diagnosis to 3 years out (YO) from end of treatment (EoT)
Whole group Male subgroup Female subgroup
Time point Mean (95% CI) NP -value Mean (95% CI) NP -value Mean (95% CI) NP -value
Height-SDS Diagnosis 0.17 (0.09–0.26) 77 0.17 (0.04–0.30) 37 0.18 (0.07–0.28) 40
1 year into treatment  0.27 ( 0.36 to  0.18) 69 o0.0001  0.21 ( 0.35 to  0.06) 32 0.03  0.32 ( 0.43 to  0.21) 37 o0.0001
End of treatment  0.31 ( 0.40 to  0.22) 68 o0.0001  0.27 ( 0.41 to  0.13) 32 o0.0001  0.35 ( 0.47 to  0.24) 36 o0.0001
1 year post EoT (1YO)  0.09 ( 0.18 to 0.00) 66 o0.0001  0.06 ( 0.20 to 0.08) 31 0.02  0.09 ( 0.20 to 0.03) 35 0.005
2 years post EoT (2YO)  0.04 ( 0.14 to 0.06) 58 o0.0001  0.09 ( 0.26 to 0.09) 23 o0.0001  0.01 ( 0.13 to 0.10) 35 0.13
3 years post EoT (3YO) 0.01 ( 0.09 to 0.11) 53 0.004  0.06 ( 0.25 to 0.13) 20 0.006 0.05 ( 0.07 to 0.17) 33 0.31
Weight-SDS Diagnosis 0.37 (0.26–0.48) 77 0.29 (0.12–0.46) 37 0.44 (0.30–0.59) 40
1 year into treatment 0.41 (0.30–0.52) 69 0.99 0.45 (0.27–0.62) 32 0.671 0.38 (0.24–0.53) 37 0.97
End of treatment 0.74 (0.62–0.85) 68 o0.0001 0.62 (0.44–0.80) 32 0.078 0.85 (0.70–1.00) 36 0.003
1 year post EoT (1YO) 0.83 (0.72–0.96) 66 o0.0001 0.72 (0.52–0.91) 31 0.003 0.96 (0.80–1.11) 35 o0.0001
2 years post EoT (2YO) 0.83 (0.70–0.96) 58 o0.0001 0.61 (0.39–0.83) 23 0.789 1.00 (0.84–1.15) 35 o0.0001
3 years post EoT (3YO) 0.78 (0.65–0.92) 53 o0.0001 0.55 (0.31–0.79) 20 0.471 0.95 (0.79–1.11) 33 o0.0001
BMI-SDS Diagnosis 0.35 (0.20–0.50) 77 0.24 (0.01–0.46) 37 0.46 (0.27–0.64) 40
1 year into treatment 0.81 (0.65–0.97) 69 o0.0001 0.87 (0.62–1.13) 32 0.001 0.77 (0.57–0.96) 37 0.13
End of treatment 1.29 (1.13–1.45) 68 o0.0001 1.11 (0.85–1.36) 32 o0.0001 1.46 (1.26–1.66) 36 o0.0001
1 year post EoT (1YO) 1.21 (1.05–1.37) 66 o0.0001 1.05 (0.79–1.31) 31 o0.0001 1.36 (1.15–1.56) 35 o0.0001
2 years post EoT (2YO) 1.14 (0.96–1.31) 58 o0.0001 0.86 (0.56–1.17) 23 0.01 1.34 (1.14–1.55) 35 o0.0001
3 years post EoT (3YO) 1.04 (0.85–1.22) 53 o0.0001 0.77 (0.43–1.10) 20 0.02 1.24 (1.03–1.45) 33 o0.0001
Abbreviations: BMI¼body mass index; N¼number of patients included in the analysis at the stated time-point; SDS¼standard deviation score. Adjusted means (95%
confidence intervals; CI) are listed. Significant P-values are displayed in bold.
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sBetween-group comparisons for BMI
There were no differences in changes in BMI-SDS from diagnosis
to 3YO in direct comparisons between groups for WCC at
diagnosis, treatment regimens, steroid agent used or gender. This
may reflect the relatively small numbers in each group.
Overall frequency of overweight/obesity
More patients were overweight or obese at 3YO than at diagnosis
(25 out of 53 (47.2%) vs 23 out of 77 (29.9%), respectively;
P¼0.01) (Table 2).
DISCUSSION
Despite the lack of cranial irradiation in current treatment
protocols, we have shown that UK survivors of childhood ALL
have increases in BMI-SDS, which persist well into follow-up. Our
data extend previous historical observations. Craig et al (1999)
demonstrated that both male and female unirradiated ALL patients
had increased BMI-SDS at EoT in a UK cohort, although such
changes were no longer significant at last follow-up. An increased
BMI-SDS at EoT was also demonstrated in a US cohort treated
without cranial irradiation, but no gender difference was
identified, possibly because patients were not followed up beyond
EoT (Baillargeon et al, 2007). Our findings reveal that females are
at particular risk for increases in BMI-SDS and that such changes
persist from EoT until at least 3YO. These data are consistent with
a US study, which not only identified increased BMI at EoT but
also that the proportion of patients overweight or obese was
unchanged 2–3 years later, with females at increased risk of such
findings (Chow et al, 2007).
Our systematic examination of height- and weight-SDS in this
study enables conclusions to be drawn about the relative
contribution of each to BMI in the whole group and in gender
subgroup analyses. Early BMI increases reflect reduced height-
SDS, whereas weight-SDS remains static. These changes are likely
due to acute suppressive effects of steroid therapy and leukaemic
illness per se on height velocity, with absent weight gain common
initially because of treatment intensity. Subsequent elevation of
BMI-SDS appears secondary to weight gain, with females
particularly susceptible. In males, BMI-SDS changes are transient,
recovering by 2YO. As males do not demonstrate weight-SDS
changes, increased BMI reflects slow height-SDS recovery. In
females, BMI increases do not appear until EoT, but then persist
until 3YO, and appear predominantly secondary to effects on
weight, as height recovers by 1YO. The weight gain observed in
females is not attributable to total steroid dose received, as males,
who receive greater cumulative doses as a result of 2 years
maintenance therapy, did not display such findings. However, the
slower height recovery seen in males is consistent with the effects
of longer steroid treatment on linear growth. Our findings suggest
a sexually dimorphic phenomenon, with the relative contributions
to persistently increased BMI from increased dietary intake,
altered metabolism and/or reduced physical activity in females
yet to be determined. Of note, females are more likely to have
reduced physical activity during cancer treatment and follow-up
(Winter et al, 2010), with female ALL survivors having also been
identified as at risk of poor physical fitness (Jarvela et al, 2010).
Survivors of childhood cancer are already at risk of adverse
long-term health outcomes, such as increased cardiovascular risk
with higher rates of myocardial infarction (Mulrooney et al, 2009),
and females appear to be at greater risk than their male
counterparts (Armstrong et al, 2007). Although small BMI-SDS
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–0.50 Figure 1 Mean height- (A), weight- (B) and BMI- (C) SDS from
diagnosis to 3 years out (YO) from end of treatment (EoT) by gender
subgroup (95% confidence intervals; CIs). Results for males are depicted by
squares; for females by circles. 1 yr Rx¼1 year of treatment. Asterisks
denote significant differences in height-, weight and BMI-SDS at that time
point when compared with values at diagnosis.
*Po0.0001;
**P¼0.001.
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sreductions have been demonstrated to lead to improvements in
cardio-metabolic risk in obese adolescents (Ford et al, 2010),
longitudinal cohort studies such as the Bogalusa Heart Study have
demonstrated that childhood overweight persists into adulthood
and is associated with increased frequency of features of the
metabolic syndrome in adulthood (Camhi et al, 2010). These
findings suggest that intervention strategies, targeting both
patients’ dietary and lifestyle choices, might be required to prevent
weight gain and physical inactivity developing during ALL
treatment and follow-up.
We recognise that our study has a number of limitations. First,
as a retrospective study, we did not have a control group for
comparison. The inclusion of longitudinal data from healthy
children, measured against the same reference data would
strengthen our observations. However, the children included in
our report were measured serially with SDS for auxological
parameters calculated against current UK standard reference data
(Cole et al, 2000). The frequency of overweight and obese in our
cohort as determined by WHO standards approaches 50% at 3YO.
The most recent reports from the UK national child measurement
programme (using the same reference data) report prevalence
rates of overweight and obesity (school year 6, 2009/2010) in our
region of 26–32% (SEPHO, 2010), similar to the prevalence in our
cohort at diagnosis (29.9%). It is therefore likely that the increased
frequency we describe is real. Second, given that the overall
median age of patients was still only 10.1 years at 3YO, it will be
important to continue to follow this cohort through puberty to
final height. As dietary intake and physical activity were not
measured in this study, it will also be important in the future to
prospectively study the impact of targeted interventions on these
parameters, and other more sophisticated auxological indices of
overweight.
In conclusion, childhood survivors of ALL treated without
cranial irradiation are at risk of BMI increases, which persist
into follow-up, with females appearing particularly susceptible.
Through targeted intervention strategies we may aim to minimise
the associated long-term morbidity and mortality in this
patient group.
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